BioNTech Acquires Biotheus for $800 Million, Enhancing Oncology Pipeline
BioNTech (NASDAQ: BNTX), the biotech giant recognized for its role in developing the COVID-19 vaccine,...
Biotheus
BioNTech Seals Acquisition of China’s Biotheus for Up to $950M
China’s Biotheus Inc. has entered into a definitive acquisition agreement with Germany-based BioNTech SE (NASDAQ:...
Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer
China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...
BioNTech Secures Global Rights to Biotheus Inc.’s Pre-Clinical Bispecific Antibody
Biotheus Inc., a biopharmaceutical company based in China, has announced that its German partner BioNTech...
Bitterroot Bio and Biotheus Inc. Join Forces to Develop Therapies for Cardiovascular Diseases
California-based biotechnology company Bitterroot Bio has announced the signing of a multi-year research collaboration agreement...
Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies
China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...
Hansoh Pharmaceutical Gets NMPA Approval for HS-20117 Bispecific Antibody Clinical Study
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...
Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based...
Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors
China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...